Danish drugmaker LEO Pharma's path to the stock market has become less certain. CEO Christophe Bourdon told Reuters that the company's owners don't believe current market conditions are supportive enough for an initial public offering (IPO), casting doubt on earlier plans for a Copenhagen listing before the end of 2026.
The company has been preparing for a possible flotation since 2021, when private-equity firm Nordic Capital invested €450 million for a minority stake. That investment came with a four- to five-year preparation window, suggesting a listing was always on the table. But Bourdon says the final decision hinges on two factors: how the business performs and whether investors are willing to back new listings. The ultimate call rests with the owners – the LEO Foundation, which holds 80%, and Nordic Capital, which holds the remainder.
Why market conditions matter for IPOs
IPOs are sensitive to market sentiment. When stock markets are choppy, investors tend to be pickier about new listings. They often demand a lower price or a smaller deal to compensate for the risk that shares might struggle in early trading. For the seller, accepting a "cheap" price can be costly in the long run – it becomes a public benchmark that shapes future fundraising, employee stock packages, and how analysts value the business.
Earlier reporting suggested LEO had lined up banks for a Copenhagen debut before the end of 2026. But more recent reports in November pointed to a potential slip into 2027. The company says it remains focused on steady growth and expanding its dermatology lineup, so it can move quickly if conditions improve.
What it means for investors
For the broader market, LEO's situation highlights how IPO windows can open and close. When volatility rises, as seen recently in AI chip stocks dragging Asian markets, new listings often get postponed or repriced. For Copenhagen, a delay means fewer opportunities for investors to buy into a well-known consumer health brand. But it also means LEO won't be forced to sell at a discount.
Because the LEO Foundation holds 80% of the company, the IPO is more optional than urgent. The foundation isn't under pressure to cash out, and Nordic Capital can afford to wait for a better window. That patience can be a double-edged sword: it may lead to a stronger debut when it happens, but it also means a stop-start pipeline for Copenhagen IPOs, and a later timeline for Nordic Capital to turn its stake into cash.
For everyday investors, the key takeaway is that IPO timing is often about market conditions as much as company fundamentals. A company can be ready to list, but if investors are nervous, the deal may be delayed or priced lower. That's why it's important to watch not just the company's performance, but also the broader market mood – including currency moves and inflation data that can shift sentiment.
LEO Pharma's situation also reflects a broader trend: private-equity-backed companies are often more flexible about timing than those that need to raise capital quickly. With a strong owner like the LEO Foundation, the company can wait for the right moment rather than accept unfavorable terms.
For now, investors should watch two things: LEO's business performance – particularly its dermatology pipeline – and the overall health of the IPO market. If conditions stabilize, a listing could still happen before the end of 2026. If not, 2027 looks more likely. Either way, the company's owners are signaling they won't rush a deal just to meet a deadline.


